RAI2 and breast cancer: In conclusion, we have shown that RAI2 depletion sensitizes KPL-1 and MCF-7 breast cancer cells to treatment with topoisomerase I and Aurora A inhibitors, indicating an additive effect with RAI2 inactivation.